儿童特应性皮炎中dupilumab、甲氨蝶呤与环孢素A的药物生存率比较
这项多中心日常实践队列研究纳入2013至2023年荷兰5家三级中心2至17岁特应性皮炎患者,比较dupilumab、甲氨蝶呤(MTX)和环孢素A(CsA)的药物生存率。共分析362例患者的502个治疗疗程,dupilumab的1年、2年、3年药物生存率分别为84.1%、72.3%、62.0%,均高于MTX(60.7%、39.3%、25.3%)和CsA(43.9%、21.5%、10.4%)。与dupilumab相比,MTX和CsA因无效和不良反应停药的风险显著更高。
要点
- dupilumab在儿童AD中3年药物生存率最高,CsA最低。
- MTX和CsA因无效及不良反应停药风险显著高于dupilumab。
- 12至17岁起始系统治疗者因无效和不良反应停药风险更高。
核心结论
- 在儿童特应性皮炎患者中,dupilumab的1年、2年、3年总体药物生存率优于MTX,CsA最低。
- 研究识别了与停药相关的特征,有助于优化患者结局。
研究设计与样本
- 多中心日常实践队列研究,纳入荷兰5家三级中心2013至2023年2至17岁特应性皮炎患者。
- 数据来自前瞻性BioDay和TREAT Netherlands注册库及电子病历,共分析362例患者的502个治疗疗程。
- 药物生存率采用Cox比例风险回归模型分析,并开展单变量和多变量Cox回归识别停药相关变量。
主要发现
- dupilumab的1年、2年、3年总体药物生存率分别为84.1%、72.3%、62.0%。
- MTX的1年、2年、3年总体药物生存率分别为60.7%、39.3%、25.3%。
- CsA的1年、2年、3年总体药物生存率分别为43.9%、21.5%、10.4%。
- 无效是最常见停药原因,共178个疗程(35.5%),多见于CsA治疗者;不良反应停药94例(18.7%)。
- 与dupilumab相比,MTX和CsA因无效停药的风险比分别为4.45(95%CI 2.38-8.34)和10.88(95%CI 6.23-19.02),因不良反应停药的风险比分别为4.39(95%CI 2.05-9.39)和3.83(95%CI 1.85-7.92)。
临床怎么用
- 在儿童中重度特应性皮炎的系统治疗选择中,dupilumab的长期药物生存率优于MTX和CsA。
- 对12至17岁起始系统治疗者需关注更高的无效和不良反应停药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dupilumab, methotrexate (MTX), and cyclosporine A (CsA) are valuable treatment options for pediatric patients with refractory moderate to severe atopic dermatitis (AD). Yet, comparative data on these treatments in pediatric patients are scarce. OBJECTIVE: To evaluate drug survival of dupilumab, MTX, and CsA, and identify associated predictors in a multicenter daily practice cohort study of pediatric patients with AD. DESIGN, SETTING, AND PARTICIPANTS: This multicenter daily practice cohort study included patients with AD aged 2 to 17 years treated with dupilumab, MTX, and/or CsA in 5 tertiary centers in the Netherlands between 2013 and 2023. Data were extracted from the prospective BioDay and TREAT Netherlands registries and electronic medical records. EXPOSURES: Dupilumab, MTX, CsA. MAIN OUTCOMES AND MEASURES: Drug survival was analyzed using Cox proportional hazard regression models. Univariable and multivariable Cox regression analyses were conducted to identify variables associated with drug discontinuation. RESULTS: A total of 502 treatment episodes in 362 unique patients were included, comprising 192 dupilumab episodes, 94 MTX episodes, and 216 CsA episodes. Overall, the mean (SD) age at treatment initiation was 12.9 (3.8) years, and 272 treatment episodes (54.2%) in female patients. The 1-year, 2-year, and 3-year overall drug survival rates, respectively, were 84.1%, 72.3%, and 62.0% for dupilumab; 60.7%, 39.3%, and 25.3% for MTX; and 43.9%, 21.5%, and 10.4% for CsA. Ineffectiveness was the most frequent reason for drug discontinuation, accounting for 178 episodes (35.5%), mostly in patients treated with CsA, followed by adverse effects in 94 patients (18.7%). Treatment with MTX and treatment with CsA were independently associated with a higher risk for drug discontinuation due to ineffectiveness (hazard ratio [HR], 4.45 [95% CI, 2.38-8.34] and HR, 10.88 [95% CI, 6.23-19.02], respectively) and adverse effects (HR, 4.39 [95% CI, 2.05-9.39] and HR, 3.83 [95% CI, 1.85-7.92], respectively) compared to treatment with dupilumab. Patients aged 12 to 17 years starting systemic treatment were independently associated with a higher risk for drug discontinuation due to ineffectiveness (HR, 1.55 [95% CI, 1.10-2.20]) and adverse effects (HR, 2.39 [95% CI, 1.33-4.30]). CONCLUSIONS AND RELEVANCE: This multicenter daily practice cohort study demonstrated a superior 1-year, 2-year, and 3-year overall drug survival for dupilumab, followed by MTX, with the lowest rates observed for CsA in pediatric patients with AD. This study also identified characteristics associated with discontinuation. These results provide insight into drug survival resulting from the effectiveness, safety, and tolerability of these systemic treatments in pediatric patients with AD and contribute to the optimization of patient outcomes.
引用
- van der Rijst LP, Kamphuis E, Schuttelaar MLA, et al. Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis. JAMA Dermatol. 2025. PMID: 39412782. doi:10.1001/jamadermatol.2024.3717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。